Far Infrared Treatment for Kidney Diseases

Kidney Failure Clinical Trial

Official title:

Phase 1 Study to Examine the Use of Far Infrared Radiation for Renal Failure.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00599391
• Other study ID #: GAAD-RF-CTP1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: January 11, 2008
• Last updated: January 2, 2009
• Start date: February 2008
• Est. completion date: February 2009

Study information

• Verified date: January 2009
• Source: GAAD Medical Research Institute Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Renal failure or kidney failure is a situation in which the kidneys fail to function adequately. It is divided into acute and chronic forms; either form may be due to a large number of other medical problems.

Description:

There are many causes of chronic kidney disease. The most common cause is diabetes mellitus. Acute renal failure is a rapidly progressive loss of renal function, generally characterized by body fluids disturbances and electrolyte derangement.

It is believed that far infrared radiation of the central nervous system, the endocrine system and the kidneys will help in the management of renal failure and a possible cure.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 10
• Est. completion date: February 2009
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• People with kidney diseases

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Kidney Failure
• Renal Insufficiency

Intervention

Radiation:
• Far Infrared Radiation (5µm to 20µm wavelength)
Far Infrared Radiation for 30 to 40 minutes per session.

Locations

Country	Name	City	State
Canada	The Centre for Incurable Diseases	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
GAAD Medical Research Institute Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Kidney Function Improvement		1 year	No
Secondary	Causes of Mortality		1 year	No